Interestingly, increased NFATc4 expression has been identified to correlate with poorer prognosis among cancer patients, similar to CAMTA1, and increased NAFTc4 activity mediates resistance to cisplatin, another platinum-based chemotherapeutic drug, in ovarian cancer, indicating that abnormal NFATc4 expression leads to treatment challenges. Here, NFATC4 is linked to cancer.